Transition Therapeutics Inc., a biopharmaceutical company, engages in developing therapeutics for various disease indications primarily in Canada. Its product candidates include ELND005 (AZD-103), a Phase II clinical trial product for the treatment of Alzheimer’s disease and neuropsychiatric disorders; TT-301 and TT-302, which are in Phase I clinical trial for the treatment of rheumatoid arthritis, Alzheimer’s disease, intracerebral hemorrhage, and traumatic brain injury; and TT401/402, a Phase I clinical trial product to treat diabetes. The company also has a pipeline of preclinical and clinical drug candidates for the treatment of anti-inflammatory and metabolic indications. It has strategic collaborations with Elan Pharma International Limited to develop and commercialize ELND005 (AZD-103); and Eli Lilly and Company. The company was formerly known as Transition Therapeutics and Diagnostics Inc. and changed its name to Transition Therapeutics Inc. on December 2000. Transition Therapeutics Inc. was founded in 1987 and is headquartered in Toronto, Canada.

Key Statistics